Publications by authors named "David C D Hope"

Claim this Profile
A
Association between the English National Health Service Diabetes Prevention Programme and incident multiple long-term conditions.
Emma Barron, Paul Chappell, Izzy Hatfield, David C D Hope, Xiaochen Ge

Nat Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Skeletal muscle loss and sarcopenia in obesity pharmacotherapy.
David C D Hope, Tricia M-M Tan

Nat Rev Endocrinol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
Emma Rose McGlone, David C D Hope, Iona Davies, Marian Dore, Rob Goldin

Biomed Pharmacother· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
David C D Hope, Saleem Ansari, Sirazum Choudhury, Kleopatra Alexiadou, Yasmin Tabbakh

Diabetes Obes Metab· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sleeve gastrectomy causes weight-loss independent improvements in hepatic steatosis.
Emma Rose McGlone, Matthieu Siebert, Marian Dore, David C D Hope, Iona Davies

Liver Int· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss.
David C D Hope, Charlotte E Hinds, Tatiana Lopes, Matthew L Vincent, Jed V Shrewsbury

Cell Rep Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity.
David C D Hope, Matthew L Vincent, Tricia M M Tan

Front Endocrinol (Lausanne)· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A glucagon analogue decreases body weight in mice via signalling in the liver.
Charlotte E Hinds, Bryn M Owen, David C D Hope, Philip Pickford, Ben Jones

Sci Rep· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals.
Chioma Izzi-Engbeaya, Walter Distaso, Anjali Amin, Wei Yang, Oluwagbemiga Idowu, David C D Hope

BMJ Open Diabetes Res Care· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century.
David C D Hope, Tricia M M Tan, Stephen R Bloom

Front Endocrinol (Lausanne)· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assembly of bioactive multilayered nanocoatings on pancreatic islet cells: incorporation of α1-antitrypsin into the coatings.
Zheng-Liang Zhi, Jashandeep Singh, Amazon L F Austin, David C D Hope, Aileen J King

Chem Commun (Camb)· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis